{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-24-011459","form_type":"8-K","ticker":"PASG","cik":"0001787297","company_name":"Passage BIO, Inc.","filed_at":"2024-08-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.525430+00:00","generated_at":"2026-05-31T11:07:46.578387+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Passage Bio reports Q2 net loss $16M; advances upliFT-D trial, out-licenses programs to GEMMABio","bullets":["Enrolled first FTD-GRN patient in Cohort 2 of upliFT-D trial; FDA agreed to expand trial to FTD-C9orf72 patients.","Out-licensed pediatric LSD programs to GEMMA Biotherapeutics; initial payments $10M, potential milestones up to $114M plus royalties.","Cash $91.8M as of June 30, 2024; cash runway extended to end of Q2 2026.","Net loss $16.0M ($0.26/share) vs $23.9M ($0.44/share) in Q2 2023; R&D and G&A expenses decreased.","Plan to present updated safety and biomarker data from Cohort 1 at ISFTD2024 in September."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-24-011459","json":"https://secwatch.observer/filing/0001558370-24-011459.json","markdown":"https://secwatch.observer/filing/0001558370-24-011459.md","text":"https://secwatch.observer/filing/0001558370-24-011459.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1787297/000155837024011459/0001558370-24-011459-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1787297/000155837024011459/pasg-20240808x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T11:07:46.578387+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}